Recombinant Protein-Based Nanoparticles: Elucidating Their Inflammatory Effects In Vivo and Their Potential as a New Therapeutic Format
暂无分享,去创建一个
N. Ferrer-Miralles | A. Villaverde | G. Opdenakker | Ò. Conchillo-Solé | E. Garcia-Fruitós | O. Cano-Garrido | A. Arís | R. Roca-Pinilla | E. Martens | E. Ugarte-Berzal | L. Boon | L. Gifre-Renom | Esther Martínez-Núñez | Teresa Luque | Ramon Roca-Pinilla
[1] Dany Qumsiyeh,et al. Profit , 2020, Placing Papers.
[2] A. Villaverde,et al. Nanostructured recombinant protein particles raise specific antibodies against the nodavirus NNV coat protein in sole. , 2020, Fish & shellfish immunology.
[3] S. Schwartz,et al. The Biological Potential Hidden in Inclusion Bodies , 2020, Pharmaceutics.
[4] A. Saneja,et al. Bacterial Inclusion Bodies: A Treasure Trove of Bioactive Proteins. , 2020, Trends in biotechnology.
[5] U. Rinas,et al. Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies , 2019, Advanced science.
[6] O. Spadiut,et al. Perspectives of inclusion bodies for bio-based products: curse or blessing? , 2018, Applied Microbiology and Biotechnology.
[7] U. Rinas,et al. Bacterial inclusion bodies are industrially exploitable amyloids , 2018, FEMS microbiology reviews.
[8] N. Ferrer-Miralles,et al. A new approach to obtain pure and active proteins from Lactococcus lactis protein aggregates , 2018, Scientific Reports.
[9] E. Vázquez,et al. Release of targeted protein nanoparticles from functional bacterial amyloids: A death star‐like approach , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[10] Esther Vázquez,et al. Bacterial Inclusion Bodies: Discovering Their Better Half. , 2017, Trends in biochemical sciences.
[11] E. Garcia-Fruitós,et al. Trends in recombinant protein use in animal production , 2017, Microbial Cell Factories.
[12] E. Vázquez,et al. Engineering tumor cell targeting in nanoscale amyloidal materials , 2017, Nanotechnology.
[13] A. Villaverde,et al. Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics. , 2016, Biomaterials.
[14] E. Vázquez,et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs , 2016, Scientific Reports.
[15] A. Villaverde,et al. Complex Particulate Biomaterials as Immunostimulant-Delivery Platforms , 2016, PloS one.
[16] J. Veciana,et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. , 2016, Acta biomaterialia.
[17] Anna Huttenlocher,et al. Neutrophil migration in infection and wound repair: going forward in reverse , 2016, Nature Reviews Immunology.
[18] Esther Vázquez,et al. Recombinant pharmaceuticals from microbial cells: a 2015 update , 2016, Microbial Cell Factories.
[19] Antonio Villaverde,et al. Functional protein aggregates: just the tip of the iceberg. , 2015, Nanomedicine.
[20] J. Veciana,et al. Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. , 2015, Nanomedicine.
[21] U. Rinas,et al. Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates. , 2014, Acta biomaterialia.
[22] S. Michaeli,et al. Intradermal air pouch leukocytosis as an in vivo test for nanoparticles , 2013, International journal of nanomedicine.
[23] P. E. Van den Steen,et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade , 2013, Critical reviews in biochemistry and molecular biology.
[24] G. Opdenakker,et al. Zymography methods for visualizing hydrolytic enzymes , 2013, Nature Methods.
[25] Antonio Villaverde,et al. The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. , 2010, Biomaterials.
[26] J. Veciana,et al. Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial , 2009 .
[27] Antonio Villaverde,et al. Recombinant protein solubility—does more mean better? , 2007, Nature Biotechnology.
[28] P. E. Van den Steen,et al. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins , 2007, Journal of leukocyte biology.
[29] A. Sali,et al. Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.
[30] R. Dwek,et al. The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.
[31] B. Plytycz,et al. Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. , 2006, Immunobiology.
[32] C. Henkel,et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] A. Sali,et al. Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.
[34] C. Janson,et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. , 2002, Acta crystallographica. Section D, Biological crystallography.
[35] A. Henney,et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. , 2002, Journal of molecular biology.
[36] R. Sciot,et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.
[37] J. Veciana,et al. Functional protein-based nanomaterial produced in GRAS microorganism: a new platform for biotechnology , 2017 .
[38] David E. Golan,et al. Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.